Clinical trials in severe sepsis with drotrecogin alfa (activated)
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for the treatment of patients with severe sepsis who are at high risk for death. The European Agency for the Evaluation of Medical Products also recommended that DrotAA could be administered to patients w...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2007
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230609/ |